Verapamil potentiation of Chironex (box-jellyfish) antivenom
Joseph W. Burnett(Bristol-Myers Squibb (United States)), John Williamson(Peterson Institute for International Economics), Iekhsan Othman(Monash University Malaysia), R. Endean(The University of Queensland), Peter J. Fenner, V. Callanan(Townsville Hospital)
Cited by 33
Related Papers
HMGB1: A Common Biomarker and Potential Target for TBI, Neuroinflammation, Epilepsy, and Cognitive Dysfunction
|Frontiers in Neuroscience|2018|318
Current strategies in extending half-lives of therapeutic proteins
|Journal of Controlled Release|2019|285
Impact of HMGB1, RAGE, and TLR4 in Alzheimer’s Disease (AD): From Risk Factors to Therapeutic Targeting
|Cells|2020|257
Mangrove rare actinobacteria: taxonomy, natural compound, and discovery of bioactivity
|Frontiers in Microbiology|2015|178
Enlightening the role of high mobility group box 1 (HMGB1) in inflammation: Updates on receptor signalling
|European Journal of Pharmacology|2019|175